Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The force of HER2 - A druggable target in NSCLC?

Cancer treatment reviews - 1 Jun 2020

Jebbink M, de Langen A J, Boelens M C, Monkhorst K, Smit E F

Abstract excerpt

Since several years targeted therapy has been part of treatment in NSCLC in subsets of patients with specific genetic alterations. One of these alterations involves HER2, a member of the ERBB family of tyrosine kinase receptors. Despite that HER2 alterations in NSCLC have been studied for years, there is still no consensus about subgroup definitions. In this review HER2 alterations in NSCLC are discussed,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoconjugates

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Randomized Controlled Trials as Topic

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 32135383
DOI: 10.1016/j.ctrv.2020.101996

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The force of HER2 - A druggable target in NSCLC?PMID 32135383Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power.Semantic proximity Read ↗

HER2 and lung cancer.Semantic proximity Read ↗

Targeting HER2 in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

[Current management and future prospect of HER-2 mutant non-small cell lung cancer].Semantic proximity Read ↗

[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target.Semantic proximity Read ↗

[Role of HER2 in NSCLC].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.